Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axis
Alessandra Morselli, Chiara Miroglio, William Kothalawala, Idan Lahat et autres
Abstract Patients with non-small cell lung cancer (NSCLC) carrying activating EGFR mutations typically respond favorably to third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib. Nevertheless, resistance almost inevitably emerges, ultimately limiting the durability of these treatments. We investigated non-genomic mechanisms enabling …
it, hu, il (code pays fourni par la source)
0 citations
bioRxiv (Cold Spring Harbor Laboratory)